Modified galectin-9 protein

Patent metadata

Field	Value
Publication number	US-9908921-B2
Application number	US-201314443558-A
Country	US
Kind code	B2
Filing date	Oct 9, 2013
Priority date	Nov 20, 2012
Publication date	Mar 6, 2018
Grant date	Mar 6, 2018

Abstract

The present invention provides galectin-9 variant having substantially the same bioactivity as in wild-type galectin-9 and being superior in protease stability, solubility, and yield. The galectin-9 variant according to the present invention is a protein including the following NCRD and the following CCRD composed of an N-terminal region and a C-terminal region. The C terminus of the NCRD and the N terminus of the CCRD are directly or indirectly bound to each other. The NCRD is (N1) a peptide composed of an amino acid sequence represented by SEQ ID NO: 1. The N-terminal region of the CCRD is (C-N1) a peptide composed of an amino acid sequence obtained by deletion of 1 to 17 amino acids in an amino acid sequence represented by SEQ ID NO: 3. The C-terminal region is (C-C1) a peptide composed of an amino acid sequence represented by SEQ ID NO: 5.

First claim

The invention claimed is:

1. A protein or a salt thereof, consisting of:
NCRD; and
CCRD, a C terminus of the NCRD and an N terminus of the CCRD being directly bound to each other, wherein:
the NCRD is
(N1) a peptide consisting of an amino acid sequence represented by SEQ ID NO: 1, or
(N2) a peptide consisting of an amino acid sequence obtained by deletion, substitution and/or insertion of between 1 and 15 amino acid residues in the amino acid sequence represented by SEQ ID NO: 1 and has a carbohydrate binding ability, and
the CCRD is
a peptide consisting of an N-terminal region and a C-terminal region and having a carbohydrate binding ability, wherein:
the N-terminal region is (C-N1) a peptide consisting of an amino acid sequence obtained by deletion of between 8 and 14 amino acid residues in an amino acid sequence of SEQ ID NO: 3, and
the C-terminal region is
(C-C1) a peptide consisting of an amino acid sequence represented by SEQ ID NO: 5, or
(C-C2) a peptide consisting of an amino acid sequence obtained by deletion, substitution and/or insertion of between 1 and 13 amino acid residues in the amino acid sequence of SEQ ID NO: 5.

2. The protein or a salt thereof according to claim 1 , wherein
the deletion of the amino acids in the N-terminal region of the CCRD is a deletion of consecutive amino acids or inconsecutive amino acids.

3. The protein or a salt thereof according to claim 1 , wherein
the deletion of the amino acids in the N-terminal region of the CCRD is a deletion of consecutive amino acids.

4. The protein or a salt thereof according to claim 3 , wherein
the deletion of the amino acids in the N-terminal region of the CCRD is a deletion of consecutive amino acids from the N terminus.

5. The protein or a salt thereof according claim 1 , wherein
at least one amino acid residue selected from the group consisting of 10th, 11th, 12th, 13th, 15th, and 17th amino acids in the amino acid sequence of SEQ ID NO: 3 of the peptide (C-N1) is proline.

6. The protein or a salt thereof according to claim 1 , wherein
10th and 11th amino acid residues in the amino acid sequence of SEQ ID NO: 3 of the peptide (C-N1) are Pro-Pro, Pro-His, or His-Pro.

7. The protein or a salt thereof according to claim 1 , wherein
12th and 13th amino acid residues in the amino acid sequence of SEQ ID NO: 3 of the peptide (C-N1) are Pro-Pro, Pro-Ala, or Ala-Pro.

8. The protein or a salt thereof according to claim 1 , wherein
the N-terminal region in the CCRD is a peptide composed of any one of amino acid sequences of SEQ ID NOs: 7 to 20.

9. The protein or a salt thereof according to claim 1 , wherein
the CCRD is a peptide composed of any one of amino acid sequences of SEQ ID NOs: 21 to 34.

10. The protein or a salt thereof according to claim 1 ,
consisting of any one of amino acid sequences of SEQ ID NOs: 35 to 48.

11. A nucleic acid comprising a nucleotide sequence which encodes the protein according to claim 1 .

12. An expression vector comprising the nucleic acid according to claim 11 .

13. A transformant comprising a nucleic acid comprised of a base sequence which encodes the protein according to claim 1 or an expression vector comprising the nucleic acid comprised of a base sequence which encodes the protein according to claim 1 .

Assignees

• Univ Kagawa Nat Univ Corp

Inventors

• Nishi Nozomu
• ITOH Aiko

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• C07K14/4726 Primary

  Lectins · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title